CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 23 enrolled
Drug / intervention
Experimental Intraosseous vancomycin 500mg in 250 mL NS +1 moredrug
Likely dose
Experimental Intraosseous vancomycin 500mg in 250 mL NSfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04042233
NCT04042233Phase 4Completed

Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol

The Methodist Hospital Research Institute·interventional·Posted Aug 1, 2019·Updated Mar 13, 2025

In Brief

A Phase 4 clinical trial evaluating Experimental Intraosseous vancomycin 500mg in 250 mL NS and Standard IV administration of vancomycin for Prosthetic Joint Infection and 2 related conditions. Completed, enrolled 23 participants across 1 site.

Detailed Summary

The objective of this study is to evaluate a novel vancomycin intraosseous administration protocol vs a standard IV vancomycin administration protocol for primary total hip arthroplasty patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedAug 1, 2019
Enrollment StartDec 31, 2019
Primary CompletionMay 25, 2022
Study CompletionSep 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.9 years ago

Interventions

Experimental Intraosseous vancomycin 500mg in 250 mL NSdrug

500mg of Vancomycin in 250 mL of normal saline will be injected into a pre-specified region of the greater trochanter during primary total hip arthroplasty.

Standard IV administration of vancomycindrug

IV antibiotics (cefepime \& vancomycin) are started in pre-op approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg, generally 1000-1750mg in 500 mL NS).